Evidence map›Paper›PMID 39113675›Full record

ArticleHaematologica2024

A phase II study of post-remission therapy with pembrolizumab in older patients with acute myeloid leukemia.

Kevin Quann, Konstantinos Lontos, Alison Sehgal, Anastasios Raptis, Annie Im, Robert L Redner, Kathleen A Dorritie, Mounzer Agha, Jing-Zhou Hou, Rafic Farah and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Kevin QuannDepartment of Medicine, Division of Hematology/Oncology, University of Pittsburgh School of Medicine, Pittsburgh PA; UPMC Hillman Cancer Center. quannka@pitt.edu.
Konstantinos LontosUPMC Hillman Cancer Center.
Alison SehgalUPMC Hillman Cancer Center.
Anastasios RaptisUPMC Hillman Cancer Center.
Annie ImDepartment of Medicine, Division of Hematology/Oncology, University of Pittsburgh School of Medicine, Pittsburgh PA; UPMC Hillman Cancer Center.
Robert L RednerDepartment of Medicine, Division of Hematology/Oncology, University of Pittsburgh School of Medicine, Pittsburgh PA; UPMC Hillman Cancer Center.
Kathleen A DorritieDepartment of Medicine, Division of Hematology/Oncology, University of Pittsburgh School of Medicine, Pittsburgh PA; UPMC Hillman Cancer Center.
Mounzer AghaUPMC Hillman Cancer Center.
Jing-Zhou HouUPMC Hillman Cancer Center.
Rafic FarahUPMC Hillman Cancer Center.
James RossettiUPMC Hillman Cancer Center.
Daniel P NormolleDepartment of Biostatistics, University of Pittsburgh School of Public Health.
Theresa L WhitesideUPMC Hillman Cancer Center, Pittsburgh, PA; Department of Pathology, University of Pittsburgh School of Medicine.
Yen-Michael Sheng HsuImmunologic Monitoring and Cellular Products Laboratory, UPMC Hillman Caner Center.
Michael BoyiadzisDepartment of Medicine, Division of Hematology/Oncology, University of Pittsburgh School of Medicine.

Funding

VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CHRISTOPHER J. BAKKENIST · 1988 to 2026
$158.0M
Small extracellular vesicles as biomarkers of prognosis and response to therapy in head and neck cancerR01DE031299 · NIDCR · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Brenda B. Diergaarde, Theresa L. Whiteside · 2023 to 2026
$2.9M
(PQ11) Reversing exosome-mediated immune suppression - a novel strategy for cancer therapyR21CA205644 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BOYIADZIS, MICHAEL, WHITESIDE, THERESA L. · 2016 to 2017
$370k
NCI NIH HHS P30 CA047904NCI NIH HHS R21 CA205644
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39113675
PMCPMC11609814

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.